Title : Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Pub. Date : 2017 Jan

PMID : 27461063






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. idelalisib transcription factor 3 Homo sapiens
2 By drug-sensitivity testing of leukemic blasts from the index patient, control samples and TCF3-PBX1 positive and negative BCP-ALL cell lines, we identified the phosphatidylinositide 3-kinase delta (p110delta) inhibitor idelalisib as an effective treatment for TCF3-PBX1 BCP-ALL. idelalisib transcription factor 3 Homo sapiens
3 Our results suggest that idelalisib is a promising treatment option for patients with TCF3-PBX1 BCP-ALL, whereas other drugs could be useful depending on the genetic context of individual patients. idelalisib transcription factor 3 Homo sapiens